- Full Year 2023 MorphoSys AG Earnings Call TranscriptMar 14, 2024€65.1Earnings
- MorphoSys AG to be Acquired by Novartis AG Call TranscriptFeb 06, 2024
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- MorphoSys AG at ASH Meeting and Exposition TranscriptDec 11, 2023
- MorphoSys AG to Discuss MANIFEST-2 Results TranscriptNov 21, 2023
- Q3 2023 MorphoSys AG Earnings Call TranscriptNov 16, 2023Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Half Year 2023 MorphoSys AG Earnings Call TranscriptAug 10, 2023Earnings
- MorphoSys AG Investor Call Focused on Pelabresib TranscriptJun 21, 2023
- MorphoSys AG at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 MorphoSys AG Earnings Call TranscriptMay 04, 2023Earnings
- Full Year 2022 MorphoSys AG Earnings Call TranscriptMar 16, 2023Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 MorphoSys AG Earnings Call TranscriptNov 17, 2022Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Q2 2022 MorphoSys AG Earnings Call TranscriptAug 04, 2022Earnings
- MorphoSys AG at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 MorphoSys AG Earnings Call TranscriptMay 05, 2022Earnings
- Full Year 2021 MorphoSys AG Earnings Call TranscriptMar 17, 2022Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 12, 2022
- Q3 2021 MorphoSys AG Earnings Call TranscriptNov 11, 2021Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- MorphoSys AG at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Half Year 2021 MorphoSys AG Earnings Call TranscriptJul 29, 2021Earnings
- MorphoSys AG To Acquire Constellation Pharmaceuticals M&A Call TranscriptJun 02, 2021
- MorphoSys AG at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Q1 2021 MorphoSys AG Earnings Call TranscriptMay 06, 2021Earnings
- Full Year 2020 MorphoSys AG Earnings Call TranscriptMar 16, 2021Earnings
- MorphoSys AG at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Q3 2020 MorphoSys AG Earnings Call TranscriptNov 12, 2020Earnings
- MorphoSys AG and Incyte Corp to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas Investor Call TranscriptSep 29, 2020
- Half Year 2020 MorphoSys AG Earnings Call TranscriptAug 06, 2020Earnings
- MorphoSys AG at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Q1 2020 MorphoSys AG Earnings Call TranscriptMay 07, 2020Earnings
- Full Year 2019 MorphoSys AG Earnings Call TranscriptMar 19, 2020Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- MorphoSys AG and Incyte Sign Global Collaboration and License Agreement for Tafasitamab Conference Call TranscriptJan 13, 2020
- Q3 2019 Morphosys AG Earnings Call TranscriptOct 30, 2019Earnings
- Half Year 2019 Morphosys AG Earnings Call TranscriptAug 07, 2019Earnings
- Morphosys AG To Discuss Results From The Primary Analysis Of The Ongoing Single-Arm Phase 2 Clinical Trial L-MIND Conference Call TranscriptMay 20, 2019
- Q1 2019 Morphosys AG Earnings Call TranscriptMay 08, 2019Earnings
- Full Year 2018 Morphosys AG Earnings Call TranscriptMar 14, 2019Earnings
Half Year 2019 Morphosys AG Earnings Call Transcript
Ladies and gentlemen, welcome to the MorphoSys Q2 Results 2019 Conference Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) Now I would like to turn the conference over to Sarah Fakih. Please go ahead.
Thank you. Good afternoon, good morning, and welcome to our Q2 2019 conference call and webcast. My name is Sarah Fakih, and I'm the Head of Corporate Communications and Investor Relations at MorphoSys. Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of MorphoSys' core technology, the progress of its current research and development programs and initiation of additional programs. Should actual results differ from the company's assumptions, ensuing actions may differ from those anticipated. You are therefore cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)